Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S Protein.
DNA vaccine
T cell response
antibody response
protein vaccine
successive site translocating inoculation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
02
2022
accepted:
28
03
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
A variety of methods have been explored to increase delivery efficiencies for DNA vaccine. However, the immunogenicity of DNA vaccines has not been satisfactorily improved. Unlike most of the previous attempts, we provided evidence suggesting that changing the injection site successively (successively site-translocated inoculation, SSTI) could significantly enhance the immunogenicity of DNA vaccines in a previous study. To simplify the strategy and to evaluate its impact on candidate SARS-CoV-2 vaccines, we immunized mice with either a SARS-CoV-2 spike-based DNA vaccine or a spike protein subunit vaccine
Identifiants
pubmed: 35514964
doi: 10.3389/fimmu.2022.875236
pmc: PMC9062103
doi:
Substances chimiques
COVID-19 Vaccines
0
Interleukin-2
0
Protein Subunits
0
Spike Glycoprotein, Coronavirus
0
Tumor Necrosis Factor-alpha
0
Vaccines, DNA
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
875236Informations de copyright
Copyright © 2022 Tian, Zhang, He, Li, Yan, Zhu, Wan and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cytokine. 2020 Jan;125:154814
pubmed: 31450102
Cytometry A. 2010 Sep;77(9):873-80
pubmed: 20629196
Vaccines (Basel). 2021 May 19;9(5):
pubmed: 34069359
Drug Discov Today. 2021 Nov;26(11):2575-2592
pubmed: 34214667
Methods Mol Biol. 2015;1325:289-302
pubmed: 26450396
Comput Struct Biotechnol J. 2021;19:2508-2517
pubmed: 33936564
Nat Mater. 2020 Aug;19(8):810-812
pubmed: 32704139
Nat Commun. 2022 Jan 10;13(1):80
pubmed: 35013199
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Curr Opin Immunol. 2021 Aug;71:111-116
pubmed: 34330017
Germs. 2013 Mar 01;3(1):26-35
pubmed: 24432284
Nat Biotechnol. 2021 Dec;39(12):1479-1482
pubmed: 34785814
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207300
Front Immunol. 2020 Sep 28;11:581807
pubmed: 33117391
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Life Sci. 2021 Feb 15;267:118919
pubmed: 33352173
Vaccines (Basel). 2019 Apr 24;7(2):
pubmed: 31022829
J Immunol. 2020 Apr 1;204(7):1703-1707
pubmed: 32122994
Vaccines (Basel). 2019 Sep 20;7(4):
pubmed: 31547081
Nature. 2012 Nov 15;491(7424):463-7
pubmed: 23075848
Clin Dev Immunol. 2012;2012:478052
pubmed: 23251217
Curr Opin Immunol. 2011 Jun;23(3):421-9
pubmed: 21530212
Front Cell Dev Biol. 2021 May 25;9:633776
pubmed: 34113610
Sci Rep. 2015 Dec 15;5:18099
pubmed: 26667202
NPJ Vaccines. 2021 Feb 22;6(1):28
pubmed: 33619260
Virology. 2011 Mar 15;411(2):206-15
pubmed: 21216425
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
J Control Release. 2010 Nov 1;147(3):342-9
pubmed: 20727926
NPJ Vaccines. 2019 Aug 1;4:33
pubmed: 31396405
Expert Rev Vaccines. 2015;14(11):1509-23
pubmed: 26313239
Vaccines (Basel). 2019 Dec 31;8(1):
pubmed: 31906072
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186
Indian J Med Res. 2021 Jan & Feb;153(1 & 2):93-114
pubmed: 33361645
Front Cell Infect Microbiol. 2021 Nov 25;11:770821
pubmed: 34900755